Recent progress in elucidating signalling proteolytic pathways in muscle wasting: Potential clinical implications

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue SUPPL1, 2013, Pages

  Polge, C ^a,b   Heng, A E ^a,b,c   Combaret, L ^a,b   Bechet D ^a,b   Taillandier, D ^a,b   Attaix, D ^a,b  

^a CRNH AUVERGNE   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c Service de Néphrologie Réanimation Médicale   (France)

Author keywords

Autophagy; MAFbx Atrogin 1; MuRF1; Muscle wasting; Protein turnover; Signalling pathway; Ubiquitin proteasome system

Indexed keywords

ATROGIN 1; GLUCOCORTICOID RECEPTOR; MUSCLE RING FINGER 1 PROTEIN; MYOSTATIN; PROTEASOME; UBIQUITIN;

HUMAN; MORBIDITY; MORTALITY; MUSCLE ATROPHY; NONHUMAN; PHOSPHORYLATION; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE SATELLITE CELL;

ANIMALIA;

AUTOPHAGY; MAFBX/ATROGIN-1; MURF1; MUSCLE WASTING; PROTEIN TURNOVER; SIGNALLING PATHWAY; UBIQUITIN-PROTEASOME SYSTEM;

BED REST; HUMANS; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 84890888103     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.08.008     Document Type: Review

References (31)

1. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002, 82:373-428.
2. Ventadour S., Attaix D. Mechanisms of skeletal muscle atrophy. Curr Opin Rheumatol 2006, 18:631-635.
3. 2+-activated, and ATP-ubiquitin-dependent proteolytic pathways in skeletal muscle from head trauma patients. Proc Natl Acad Sci U S A 1996, 93:2714-2718.
4. Vazeille E., Codran A., Claustre A., Averous J., Listrat A., Béchet D., et al. The ubiquitin-proteasome and the mitochondria-associated apoptotic pathways are sequentially downregulated during recovery after immobilization-induced muscle atrophy. Am J Physiol Endocrinol Metab 2008, 295:E1181-E1190.
5. Polge C., Heng A.-E., Jarzaguet M., Ventadour S., Claustre A., Combaret L., et al. Muscle actin is polyubiquitinylated invitro and invivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J 2011, 25:3790-3802.
6. Sandri M. New findings of lysosomal proteolysis in skeletal muscle. Curr Opin Clin Nutr Metab Care 2011, 14:223-229.
7. Bodine S.C., Latres E., Baumhueter S., Lai V.K.M., Nunez L., Clarke B.A., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294:1704-1708.
8. Gomes M.D., Lecker S.H., Jagoe R.T., Navon A., Goldberg A.L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 2001, 98:14440-14445.
9. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412.
10. Cai D., Frantz J.D., Tawa N.E., Melendez P.A., Oh B.C., Lidov H.G., et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 2004, 119:285-298.
11. Raffaello A., Milan G., Masiero E., Carnio S., Lee D., Lanfranchi G., et al. JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy. J Cell Biol 2010, 191:101-113.
12. Romanello V., Guadagnin E., Gomes L., Roder I., Sandri C., Petersen Y., et al. Mitochondrial fission and remodelling contributes to muscle atrophy. EMBO J 2010, 29:1774-1785.
13. Attaix D., Bechet D. FoxO3 controls dangerous proteolytic liaisons. Cell Metab 2007, 6:425-427.
14. Mammucari C., Milan G., Romanello V., Masiero E., Rudolf R., Del Piccolo P., et al. FoxO3 controls autophagy in skeletal muscle invivo. Cell Metab 2007, 6:458-471.
15. Zhao J., Brault J.J., Schild A., Cao P., Sandri M., Schiaffino S., et al. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 2007, 6:472-483.
16. Paul P.K., Gupta S.K., Bhatnagar S., Panguluri S.K., Darnay B.G., Choi Y., et al. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J Cell Biol 2010, 191:1395-1411.
17. Paul P.K., Kumar A. TRAF6 coordinates the activation of autophagy and ubiquitin-proteasome systems in atrophying skeletal muscle. Autophagy 2011, 7:555-556.
18. Inoki K., Li Y., Xu T., Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signalling. Genes Dev 2003, 17:1829-1834.
19. Cheng S.W., Fryer L.G., Carling D., Shepherd P.R. Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem 2004, 279:15719-15722.
20. Lantier L., Mounier R., Leclerc J., Pende M., Foretz M., Viollet B. Coordinated maintenance of muscle cell size control by AMP-activated protein kinase. FASEB J 2010, 24:3555-3561.
21. Shimizu N., Yoshikawa N., Ito N., Maruyama T., Suzuki Y., Takeda S., et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab 2011, 13:170-182.
22. Attaix D., Baracos V.E. MAFbx/Atrogin-1 expression is a poor index of muscle proteolysis. Curr Opin Clin Nutr Metab Care 2010, 13:223-224.
23. Lagirand-Cantaloube J., Cornille K., Csibi A., Batonnet-Pichon S., Leibovitch M.P., Leibovitch S.A. Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy invivo. PLoS One 2009, 4:e4973.
24. Lagirand-Cantaloube J., Offner N., Csibi A., Leibovitch M.P., Batonnet-Pichon S., Tintignac L.A., et al. The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J 2008, 27:1266-1276.
25. Csibi A., Leibovitch M.P., Cornille K., Tintignac L.A., Leibovitch S.A. MAFbx/Atrogin-1 controls the activity of the initiation factor eIF3-f in skeletal muscle atrophy by targeting multiple C-terminal lysines. J Biol Chem 2009, 284:4413-4421.
26. Csibi A., Cornille K., Leibovitch M.P., Poupon A., Tintignac L.A., Sanchez A.M., et al. The translation regulatory subunit eIF3f controls the kinase-dependent mTOR signalling required for muscle differentiation and hypertrophy in mouse. PLoS One 2010, 5:e8994.
27. Combaret L., Adegoke O.A., Bedard N., Baracos V., Attaix D., Wing S.S. USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states. Am J Physiol Endocrinol Metab 2005, 288:E693-E700.
28. Sundaram P., Pang Z., Miao M., Yu L., Wing S.S. USP19-deubiquitinating enzyme regulates levels of major myofibrillar proteins in L6 muscle cells. Am J Physiol Endocrinol Metab 2009, 297:E1283-E1290.
29. Gilson H., Schakman O., Combaret L., Lause P., Grobet L., Attaix D., et al. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 2007, 148:452-460.
30. Zhou X., Wang J.L., Lu J., Song Y., Kwak K.S., Jiao Q., et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142:531-543.
31. Attaix D., Baracos V.E., Pichard C. Muscle wasting: a crosstalk between protein synthesis and breakdown signalling. Curr Opin Clin Nutr Metab Care 2012, 15:209-210.